Abstract
Pretraining electronic health record (EHR) data through language models by treating patient trajectories as natural language sentences has improved various medical tasks. However, EHR pretraining models have never been utilized in adverse drug event (ADE) prediction. Here, we propose a novel pretraining scheme for common data model (CDM) based EHR data, named CDM-BERT. We utilized diagnosis, prescription, measurement, and procedure domains from observational medical outcomes partnership (OMOP)-CDM. We newly adopted domain embedding (DE) to simplify pretraining procedure and to improve comprehension of medical context. ADE prediction was selected as a finetuning task. For drug groups, we included nonsteroidal anti-inflammatory drugs (NSAID), anticoagulants (AC), glucocorticoids (GC), and chemotherapy (Chemo). For corresponding adverse events, we selected peptic ulcer (PU), intracranial hemorrhage (ICH), osteoporosis (OP), and neutropenic fever (NF), respectively. CDM-BERT was validated by internal and external datasets with 510,879 and 419,505 adult inpatients. CDM-BERT outperformed all the other baselines in all cohorts, demonstrating the effectiveness of DE (area under the receiver operating characteristic curve (AUROC) of 0.977, 0.908, 0.980, 0.989 for NSAID-PU, AC-ICH, GC-OP, Chemo-NF cohorts in internal validation, and 0.967, 0.960, 0.972, 0.959 in external validation, respectively). We also identified important features for each cohort, and several prior studies and clinical knowledge suggested the results. CDM-BERT has demonstrated its potential as a foundation model through its prediction performance, interpretability, and compatibility.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board (IRB) of Seoul National University Hospital (IRB approval No. 2204-001-1310) approved the study with a waiver of informed consent, considering that our study used retrospective and observational EHR data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.